Lipocine Inc.
For the period ended Oct 7, 2026. Filed Oct 7, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 7, 2026 · Filed Oct 7, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Hematologic
Hematologic
Increases in hematocrit levels, reflective of increases in red blood cell mass, may require lowering of dose or discontinuation of therapy. Check hematocrit prior to initiating treatment. It would also be appropriate to re-evaluate hematocrit 3 to 6 months after starting treatment, and then annually. If hematocrit becomes elevated, stop therapy until hematocrit decreases to an acceptable level. If TLANDO is restarted and again causes hematocrit to become elevated, stop TLANDO permanently. An increase in red blood cell mass may increase the risk of thromboembolic events.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.